Capital Fund Management (CFM)
KDNY

Capital Fund Management (CFM)’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Capital Fund Management (CFM)’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,720
Closed -$130K – 2352
2018
Q2 		$130K Buy
+3,720
New +$143K ﹤0.01% 1923

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Capital Fund Management (CFM)'s KDNY Position: Q3 2018 in Review

Capital Fund Management (CFM) sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2018, closing a stake of 3,720 shares — an estimated $130K sold.

Capital Fund Management (CFM) first reported a position in KDNY in Q2 2018 and held it in 1 quarter. The position peaked at $130K in Q2 2018. 87 funds tracked by Wall St. Rank hold KDNY as of Q3 2018.

  • Capital Fund Management (CFM) reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 3,720 Chinook Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $130K.
  • Capital Fund Management (CFM) first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Capital Fund Management (CFM)'s Chinook Therapeutics, Inc. Common Stock position peaked at $130K in Q2 2018.
  • 87 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2018, filed 14 Nov 2018.